Browsing Tag
MOMENTUM trial
1 post
Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data
Corcept Therapeutics says 27.3% of resistant hypertension patients may have hypercortisolism. Read what the MOMENTUM data could mean next.